A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia
Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidep...
Gespeichert in:
Veröffentlicht in: | International journal of geriatric psychiatry 2000-04, Vol.15 (4), p.295-305 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 305 |
---|---|
container_issue | 4 |
container_start_page | 295 |
container_title | International journal of geriatric psychiatry |
container_volume | 15 |
creator | Karlsson, Ingvar Godderis, Jan Augusto De Mendonça Lima, Carlos Nygaard, Harald Simányi, Margarete Taal, Maarja Eglin, Mirjam |
description | Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/(SICI)1099-1166(200004)15:4<295::AID-GPS105>3.0.CO;2-C |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21100373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21100373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4365-8a82e79fe8625edd9b74da80d33e885612bc407e0920dcd16b6705093c64187f3</originalsourceid><addsrcrecordid>eNqFkeuK1DAUx4so7rj6CpJPsgt2zKVt2lUWxuqOA4Mjjrdvh7Q5ZaNtU5MO6zyU72jGDougYAgEkv8lnF8UXTI6Z5TyZ2fbVbk6Z7QoYsay7IzTsJJzll4kL3iRXlwsVq_i5bsto-mlmNN5uXnO4_JONLu13I1mNM_TOOOCnkQPvP8aEoqC5fejE0ZlJiXPZ9HPBXGq17YzHvVTou2uajGuWtNrUttuUM542xPbkPEaCTaNqVW9J8FCvGpw3B-eajOq1g5OdUcPajJa0hnVe3SmJ2Fjq9G1-1CBg0Mf2sigRoP96MmNGa-Jdb9PuxuDsZ0CbPCoEYOnC0KjHkb3GtV6fHQ8T6OPV68_lG_i9Wa5KhfruE5Elsa5yjnKosE84ylqXVQy0SqnWggMI8kYr-qESqQFp7rWLKsySVNaiDpLWC4bcRo9mXIHZ7_v0I8Q5lNj26oe7c4DZwGSkCIIP03C2lnvHTYwONMptwdG4QAS4AASDlTgQAUmkMBSSCCABAggYQIJAiiUG-BQhuDHxx_sqg71H7ETuSD4MgluTIv7v2r_0_rP0uNNiI6naONH_HEbrdw3yKSQKXx-u4ScXuXJy_dbWItftYrLGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21100373</pqid></control><display><type>article</type><title>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Karlsson, Ingvar ; Godderis, Jan ; Augusto De Mendonça Lima, Carlos ; Nygaard, Harald ; Simányi, Margarete ; Taal, Maarja ; Eglin, Mirjam</creator><creatorcontrib>Karlsson, Ingvar ; Godderis, Jan ; Augusto De Mendonça Lima, Carlos ; Nygaard, Harald ; Simányi, Margarete ; Taal, Maarja ; Eglin, Mirjam</creatorcontrib><description>Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0885-6230</identifier><identifier>EISSN: 1099-1166</identifier><identifier>DOI: 10.1002/(SICI)1099-1166(200004)15:4<295::AID-GPS105>3.0.CO;2-C</identifier><identifier>PMID: 10767728</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antidepressive Agents, Second-Generation - adverse effects ; Antidepressive Agents, Second-Generation - pharmacology ; Antidepressive Agents, Second-Generation - therapeutic use ; citalopram ; Citalopram - adverse effects ; Citalopram - pharmacology ; Citalopram - therapeutic use ; dementia ; Dementia - complications ; depression ; Depressive Disorder - complications ; Depressive Disorder - drug therapy ; Double-Blind Method ; elderly ; Europe ; Female ; Humans ; Male ; mianserin ; Mianserin - adverse effects ; Mianserin - pharmacology ; Mianserin - therapeutic use ; Psychiatric Status Rating Scales ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome</subject><ispartof>International journal of geriatric psychiatry, 2000-04, Vol.15 (4), p.295-305</ispartof><rights>Copyright © 2000 John Wiley & Sons, Ltd.</rights><rights>Copyright 2000 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4365-8a82e79fe8625edd9b74da80d33e885612bc407e0920dcd16b6705093c64187f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291099-1166%28200004%2915%3A4%3C295%3A%3AAID-GPS105%3E3.0.CO%3B2-C$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291099-1166%28200004%2915%3A4%3C295%3A%3AAID-GPS105%3E3.0.CO%3B2-C$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10767728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karlsson, Ingvar</creatorcontrib><creatorcontrib>Godderis, Jan</creatorcontrib><creatorcontrib>Augusto De Mendonça Lima, Carlos</creatorcontrib><creatorcontrib>Nygaard, Harald</creatorcontrib><creatorcontrib>Simányi, Margarete</creatorcontrib><creatorcontrib>Taal, Maarja</creatorcontrib><creatorcontrib>Eglin, Mirjam</creatorcontrib><title>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</title><title>International journal of geriatric psychiatry</title><addtitle>Int. J. Geriat. Psychiatry</addtitle><description>Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley & Sons, Ltd.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Antidepressive Agents, Second-Generation - pharmacology</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>citalopram</subject><subject>Citalopram - adverse effects</subject><subject>Citalopram - pharmacology</subject><subject>Citalopram - therapeutic use</subject><subject>dementia</subject><subject>Dementia - complications</subject><subject>depression</subject><subject>Depressive Disorder - complications</subject><subject>Depressive Disorder - drug therapy</subject><subject>Double-Blind Method</subject><subject>elderly</subject><subject>Europe</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>mianserin</subject><subject>Mianserin - adverse effects</subject><subject>Mianserin - pharmacology</subject><subject>Mianserin - therapeutic use</subject><subject>Psychiatric Status Rating Scales</subject><subject>Severity of Illness Index</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0885-6230</issn><issn>1099-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkeuK1DAUx4so7rj6CpJPsgt2zKVt2lUWxuqOA4Mjjrdvh7Q5ZaNtU5MO6zyU72jGDougYAgEkv8lnF8UXTI6Z5TyZ2fbVbk6Z7QoYsay7IzTsJJzll4kL3iRXlwsVq_i5bsto-mlmNN5uXnO4_JONLu13I1mNM_TOOOCnkQPvP8aEoqC5fejE0ZlJiXPZ9HPBXGq17YzHvVTou2uajGuWtNrUttuUM542xPbkPEaCTaNqVW9J8FCvGpw3B-eajOq1g5OdUcPajJa0hnVe3SmJ2Fjq9G1-1CBg0Mf2sigRoP96MmNGa-Jdb9PuxuDsZ0CbPCoEYOnC0KjHkb3GtV6fHQ8T6OPV68_lG_i9Wa5KhfruE5Elsa5yjnKosE84ylqXVQy0SqnWggMI8kYr-qESqQFp7rWLKsySVNaiDpLWC4bcRo9mXIHZ7_v0I8Q5lNj26oe7c4DZwGSkCIIP03C2lnvHTYwONMptwdG4QAS4AASDlTgQAUmkMBSSCCABAggYQIJAiiUG-BQhuDHxx_sqg71H7ETuSD4MgluTIv7v2r_0_rP0uNNiI6naONH_HEbrdw3yKSQKXx-u4ScXuXJy_dbWItftYrLGg</recordid><startdate>200004</startdate><enddate>200004</enddate><creator>Karlsson, Ingvar</creator><creator>Godderis, Jan</creator><creator>Augusto De Mendonça Lima, Carlos</creator><creator>Nygaard, Harald</creator><creator>Simányi, Margarete</creator><creator>Taal, Maarja</creator><creator>Eglin, Mirjam</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200004</creationdate><title>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</title><author>Karlsson, Ingvar ; Godderis, Jan ; Augusto De Mendonça Lima, Carlos ; Nygaard, Harald ; Simányi, Margarete ; Taal, Maarja ; Eglin, Mirjam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4365-8a82e79fe8625edd9b74da80d33e885612bc407e0920dcd16b6705093c64187f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Antidepressive Agents, Second-Generation - pharmacology</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>citalopram</topic><topic>Citalopram - adverse effects</topic><topic>Citalopram - pharmacology</topic><topic>Citalopram - therapeutic use</topic><topic>dementia</topic><topic>Dementia - complications</topic><topic>depression</topic><topic>Depressive Disorder - complications</topic><topic>Depressive Disorder - drug therapy</topic><topic>Double-Blind Method</topic><topic>elderly</topic><topic>Europe</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>mianserin</topic><topic>Mianserin - adverse effects</topic><topic>Mianserin - pharmacology</topic><topic>Mianserin - therapeutic use</topic><topic>Psychiatric Status Rating Scales</topic><topic>Severity of Illness Index</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karlsson, Ingvar</creatorcontrib><creatorcontrib>Godderis, Jan</creatorcontrib><creatorcontrib>Augusto De Mendonça Lima, Carlos</creatorcontrib><creatorcontrib>Nygaard, Harald</creatorcontrib><creatorcontrib>Simányi, Margarete</creatorcontrib><creatorcontrib>Taal, Maarja</creatorcontrib><creatorcontrib>Eglin, Mirjam</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>International journal of geriatric psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karlsson, Ingvar</au><au>Godderis, Jan</au><au>Augusto De Mendonça Lima, Carlos</au><au>Nygaard, Harald</au><au>Simányi, Margarete</au><au>Taal, Maarja</au><au>Eglin, Mirjam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</atitle><jtitle>International journal of geriatric psychiatry</jtitle><addtitle>Int. J. Geriat. Psychiatry</addtitle><date>2000-04</date><risdate>2000</risdate><volume>15</volume><issue>4</issue><spage>295</spage><epage>305</epage><pages>295-305</pages><issn>0885-6230</issn><eissn>1099-1166</eissn><abstract>Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>10767728</pmid><doi>10.1002/(SICI)1099-1166(200004)15:4<295::AID-GPS105>3.0.CO;2-C</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0885-6230 |
ispartof | International journal of geriatric psychiatry, 2000-04, Vol.15 (4), p.295-305 |
issn | 0885-6230 1099-1166 |
language | eng |
recordid | cdi_proquest_miscellaneous_21100373 |
source | MEDLINE; Wiley Online Library All Journals |
subjects | Aged Aged, 80 and over Antidepressive Agents, Second-Generation - adverse effects Antidepressive Agents, Second-Generation - pharmacology Antidepressive Agents, Second-Generation - therapeutic use citalopram Citalopram - adverse effects Citalopram - pharmacology Citalopram - therapeutic use dementia Dementia - complications depression Depressive Disorder - complications Depressive Disorder - drug therapy Double-Blind Method elderly Europe Female Humans Male mianserin Mianserin - adverse effects Mianserin - pharmacology Mianserin - therapeutic use Psychiatric Status Rating Scales Severity of Illness Index Survival Analysis Treatment Outcome |
title | A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A25%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomised,%20double-blind%20comparison%20of%20the%20efficacy%20and%20safety%20of%20citalopram%20compared%20to%20mianserin%20in%20elderly,%20depressed%20patients%20with%20or%20without%20mild%20to%20moderate%20dementia&rft.jtitle=International%20journal%20of%20geriatric%20psychiatry&rft.au=Karlsson,%20Ingvar&rft.date=2000-04&rft.volume=15&rft.issue=4&rft.spage=295&rft.epage=305&rft.pages=295-305&rft.issn=0885-6230&rft.eissn=1099-1166&rft_id=info:doi/10.1002/(SICI)1099-1166(200004)15:4%3C295::AID-GPS105%3E3.0.CO;2-C&rft_dat=%3Cproquest_cross%3E21100373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21100373&rft_id=info:pmid/10767728&rfr_iscdi=true |